vs
Aclaris Therapeutics, Inc.（ACRS）与爱齐科技（ALGN）财务数据对比。点击上方公司名可切换其他公司
爱齐科技的季度营收约是Aclaris Therapeutics, Inc.的808.9倍（$1.0B vs $1.3M）。爱齐科技净利率更高（13.0% vs -1528.6%，领先1541.5%）。爱齐科技同比增速更快（5.3% vs -85.9%）。爱齐科技自由现金流更多（$187.3M vs $-13.2M）。过去两年爱齐科技的营收复合增速更高（2.5% vs -26.5%）
Aclaris Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对免疫疾病、炎症性疾病和皮肤病的创新靶向疗法，核心管线覆盖斑秃、白癜风等未满足临床需求领域，致力于为全球相关患者提供新型治疗选择。
爱齐科技是一家全球知名医疗设备企业，主营设计、生产及销售隐适美透明矫治器、iTero口内扫描仪及配套服务，客户覆盖正畸医师、全科牙医，面向修复、美容牙科领域，业务分为透明矫治器、扫描仪及服务两大板块，可满足青少年等不同群体的正畸需求
ACRS vs ALGN — 直观对比
营收规模更大
ALGN
是对方的808.9倍
$1.3M
营收增速更快
ALGN
高出91.2%
-85.9%
净利率更高
ALGN
高出1541.5%
-1528.6%
自由现金流更多
ALGN
多$200.4M
$-13.2M
两年增速更快
ALGN
近两年复合增速
-26.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3M | $1.0B |
| 净利润 | $-19.8M | $135.8M |
| 毛利率 | 58.9% | 65.3% |
| 营业利润率 | -1755.5% | 14.8% |
| 净利率 | -1528.6% | 13.0% |
| 营收同比 | -85.9% | 5.3% |
| 净利润同比 | 79.5% | 30.8% |
| 每股收益（稀释后） | $-0.16 | $1.88 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACRSALGN
| Q4 25 | $1.3M | $1.0B | ||
| Q3 25 | $3.3M | $995.7M | ||
| Q2 25 | $1.8M | $1.0B | ||
| Q1 25 | $1.5M | $979.3M | ||
| Q4 24 | $9.2M | $995.2M | ||
| Q3 24 | $4.3M | $977.9M | ||
| Q2 24 | $2.8M | $1.0B | ||
| Q1 24 | $2.4M | $997.4M |
净利润ACRSALGN
| Q4 25 | $-19.8M | $135.8M | ||
| Q3 25 | $-14.6M | $56.8M | ||
| Q2 25 | $-15.4M | $124.6M | ||
| Q1 25 | $-15.1M | $93.2M | ||
| Q4 24 | $-96.6M | $103.8M | ||
| Q3 24 | $-7.6M | $116.0M | ||
| Q2 24 | $-11.0M | $96.6M | ||
| Q1 24 | $-16.9M | $105.0M |
毛利率ACRSALGN
| Q4 25 | 58.9% | 65.3% | ||
| Q3 25 | 83.7% | 64.2% | ||
| Q2 25 | 71.0% | 69.9% | ||
| Q1 25 | 65.2% | 69.5% | ||
| Q4 24 | 92.3% | 70.0% | ||
| Q3 24 | 85.0% | 69.7% | ||
| Q2 24 | 77.4% | 70.3% | ||
| Q1 24 | 66.3% | 70.0% |
营业利润率ACRSALGN
| Q4 25 | -1755.5% | 14.8% | ||
| Q3 25 | -519.8% | 9.7% | ||
| Q2 25 | -1035.9% | 16.1% | ||
| Q1 25 | -1242.9% | 13.4% | ||
| Q4 24 | -1082.3% | 14.5% | ||
| Q3 24 | -240.9% | 16.6% | ||
| Q2 24 | -464.7% | 14.3% | ||
| Q1 24 | -789.4% | 15.5% |
净利率ACRSALGN
| Q4 25 | -1528.6% | 13.0% | ||
| Q3 25 | -443.0% | 5.7% | ||
| Q2 25 | -868.3% | 12.3% | ||
| Q1 25 | -1036.8% | 9.5% | ||
| Q4 24 | -1048.3% | 10.4% | ||
| Q3 24 | -174.6% | 11.9% | ||
| Q2 24 | -397.2% | 9.4% | ||
| Q1 24 | -706.5% | 10.5% |
每股收益（稀释后）ACRSALGN
| Q4 25 | $-0.16 | $1.88 | ||
| Q3 25 | $-0.12 | $0.78 | ||
| Q2 25 | $-0.13 | $1.72 | ||
| Q1 25 | $-0.12 | $1.27 | ||
| Q4 24 | $-1.21 | $1.40 | ||
| Q3 24 | $-0.11 | $1.55 | ||
| Q2 24 | $-0.15 | $1.28 | ||
| Q1 24 | $-0.24 | $1.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.0M | $1.1B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $103.1M | $4.0B |
| 总资产 | $160.5M | $6.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACRSALGN
| Q4 25 | $20.0M | $1.1B | ||
| Q3 25 | $25.3M | $1.0B | ||
| Q2 25 | $25.4M | $901.2M | ||
| Q1 25 | $30.4M | $873.0M | ||
| Q4 24 | $24.6M | $1.0B | ||
| Q3 24 | $47.7M | $1.0B | ||
| Q2 24 | $22.8M | $761.4M | ||
| Q1 24 | $35.8M | $865.8M |
股东权益ACRSALGN
| Q4 25 | $103.1M | $4.0B | ||
| Q3 25 | $120.1M | $4.0B | ||
| Q2 25 | $131.7M | $3.9B | ||
| Q1 25 | $144.1M | $3.8B | ||
| Q4 24 | $155.6M | $3.9B | ||
| Q3 24 | $130.2M | $3.9B | ||
| Q2 24 | $133.8M | $3.8B | ||
| Q1 24 | $142.0M | $3.8B |
总资产ACRSALGN
| Q4 25 | $160.5M | $6.2B | ||
| Q3 25 | $175.5M | $6.2B | ||
| Q2 25 | $189.1M | $6.2B | ||
| Q1 25 | $198.1M | $6.1B | ||
| Q4 24 | $220.3M | $6.2B | ||
| Q3 24 | $182.4M | $6.4B | ||
| Q2 24 | $161.1M | $6.2B | ||
| Q1 24 | $174.1M | $6.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-13.1M | $223.2M |
| 自由现金流经营现金流 - 资本支出 | $-13.2M | $187.3M |
| 自由现金流率自由现金流/营收 | -1015.8% | 17.9% |
| 资本支出强度资本支出/营收 | 1.9% | 3.4% |
| 现金转化率经营现金流/净利润 | — | 1.64× |
| 过去12个月自由现金流最近4个季度 | $-47.2M | $490.8M |
8季度趋势，按日历期对齐
经营现金流ACRSALGN
| Q4 25 | $-13.1M | $223.2M | ||
| Q3 25 | $-10.9M | $188.7M | ||
| Q2 25 | $-10.0M | $128.7M | ||
| Q1 25 | $-13.1M | $52.7M | ||
| Q4 24 | $-8.9M | $286.1M | ||
| Q3 24 | $22.0M | $263.7M | ||
| Q2 24 | $-12.3M | $159.8M | ||
| Q1 24 | $-20.8M | $28.7M |
自由现金流ACRSALGN
| Q4 25 | $-13.2M | $187.3M | ||
| Q3 25 | $-11.0M | $169.0M | ||
| Q2 25 | $-10.0M | $107.2M | ||
| Q1 25 | $-13.1M | $27.4M | ||
| Q4 24 | — | $263.1M | ||
| Q3 24 | — | $233.9M | ||
| Q2 24 | $-12.3M | $106.4M | ||
| Q1 24 | $-20.9M | $19.3M |
自由现金流率ACRSALGN
| Q4 25 | -1015.8% | 17.9% | ||
| Q3 25 | -332.1% | 17.0% | ||
| Q2 25 | -563.5% | 10.6% | ||
| Q1 25 | -900.3% | 2.8% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | -446.0% | 10.3% | ||
| Q1 24 | -873.6% | 1.9% |
资本支出强度ACRSALGN
| Q4 25 | 1.9% | 3.4% | ||
| Q3 25 | 0.7% | 2.0% | ||
| Q2 25 | 1.2% | 2.1% | ||
| Q1 25 | 3.0% | 2.6% | ||
| Q4 24 | 0.0% | 2.3% | ||
| Q3 24 | 0.0% | 3.0% | ||
| Q2 24 | 0.5% | 5.2% | ||
| Q1 24 | 5.6% | 0.9% |
现金转化率ACRSALGN
| Q4 25 | — | 1.64× | ||
| Q3 25 | — | 3.33× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 0.57× | ||
| Q4 24 | — | 2.76× | ||
| Q3 24 | — | 2.27× | ||
| Q2 24 | — | 1.66× | ||
| Q1 24 | — | 0.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
